Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma




Martini Alberto, Wever Lieke, Soeterik Timo F. W., Rakauskas Arnas, Fankhauser Christian Daniel, Grogg Josias Bastian, Checcucci Enrico, Amparore Daniele, Haiquel Luciano, Rodriguez-Sanchez Lara, Ploussard Guillaume, Qiang Peng, Affentranger Andres, Marquis Alessandro, Marra Giancarlo, Ettala Otto, Zattoni Fabio, Falagario Ugo Giovanni, De Angelis Mario, Kesch Claudia, Apfelbeck Maria, Al-Hammouri Tarek, Kretschmer Alexander, Kasivisvanathan Veeru, Preisser Felix, Lefebvre Emilie, Olivier Jonathan, Radtke Jan Philipp, Briganti Alberto, Montorsi Francesco, Carrieri Giuseppe, Dal Moro Fabrizio, Boström Peter, Jambor Ivan, Gontero Paolo, Chiu Peter K., John Hubert, Macek Petr, Porpiglia Francesco, Hermanns Thomas, van den Bergh Roderick C.N., van Basten Jean-Paul A., Gandaglia Giorgio, Valerio Massimo

2023

Journal of Urology

The Journal of urology

J Urol

210

1

117

127

0022-5347

1527-3792

DOIhttps://doi.org/10.1097/JU.0000000000003442

https://www.auajournals.org/doi/10.1097/JU.0000000000003442

https://research.utu.fi/converis/portal/detail/Publication/180705069



PURPOSE
Bilateral extended pelvic lymph node dissection at the time of radical prostatectomy is the current standard of care if pelvic lymph node dissection is indicated; often, however, pelvic lymph node dissection is performed in pN0 disease. With the more accurate staging achieved with magnetic resonance imaging-targeted biopsies for prostate cancer diagnosis, the indication for bilateral extended pelvic lymph node dissection may be revised. We aimed to assess the feasibility of unilateral extended pelvic lymph node dissection in the era of modern prostate cancer imaging.

MATERIALS AND METHODS
We analyzed a multi-institutional data set of men with cN0 disease diagnosed by magnetic resonance imaging-targeted biopsy who underwent prostatectomy and bilateral extended pelvic lymph node dissection. The outcome of the study was lymph node invasion contralateral to the prostatic lobe with worse disease features, ie, dominant lobe. Logistic regression to predict lymph node invasion contralateral to the dominant lobe was generated and internally validated.

RESULTS
Overall, data from 2,253 patients were considered. Lymph node invasion was documented in 302 (13%) patients; 83 (4%) patients had lymph node invasion contralateral to the dominant prostatic lobe. A model including prostate-specific antigen, maximum diameter of the index lesion, seminal vesicle invasion on magnetic resonance imaging, International Society of Urological Pathology grade in the nondominant side, and percentage of positive cores in the nondominant side achieved an area under the curve of 84% after internal validation. With a cutoff of contralateral lymph node invasion of 1%, 602 (27%) contralateral pelvic lymph node dissections would be omitted with only 1 (1.2%) lymph node invasion missed.

CONCLUSIONS
Pelvic lymph node dissection could be omitted contralateral to the prostate lobe with worse disease features in selected patients. We propose a model that can help avoid contralateral pelvic lymph node dissection in almost one-third of cases.


Last updated on 2025-27-03 at 22:04